Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,392.21 -25.47 -0.18%
TOPIX 1,166.23 -0.32 -0.03%
HANG SENG 22,749.87 53.86 0.24%

Durata Therapeutics to Present at Bank of America Merrill Lynch 2013 Healthcare Conference

Durata Therapeutics to Present at Bank of America Merrill Lynch 2013
Healthcare Conference

CHICAGO, May 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX)
announced today that Paul R. Edick, CEO, will present an overview of the
Company at the Bank of America Merrill Lynch Healthcare Conference on Tuesday,
May 14, 2013 at 10:40 AM PT at the Encore at the Wynn Las Vegas.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.

CONTACT: Allison Wey
         Durata Therapeutics, Inc.
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017

Durata Therapeutics, Inc. Logo
Sponsored Links
Sponsored Links